Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00854061 · ClinicalTrials.gov registry record · Phase 3
Study of T-PRED(TM) Compared to Pred Forte(R) II
A Phase 3 study of Cataract, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 3
- Development phase
- 172
- Enrollment target
- 1
- Study location
NCT00854061: Completed Phase 3 study of Cataract, sponsored by Bausch & Lomb Incorporated.
NCT00854061 is a Phase 3 study of Cataract that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 172 participants, below the 226-participant average among 83 other Cataract trials with a reported enrollment target (24% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00854061, a Phase 3 study of Cataract, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 172 participants
- Enrollment target
- 1
- Study location
Study Summary
Study of T-PRED(TM) Compared to Pred Forte(R)
Conditions Studied
Interventions
- DRUG T-Pred
- DRUG Pred Forte
Study Locations (1)
California
- ISTA Pharmaceuticals, Inc. - Irvine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 172 participants |
| Start Date | 2009-02 |
| Est. Completion | 2009-08 |
| Phase | Phase 3 |
What the finished NCT00854061 record still lists
NCT00854061 is an interventional study that assigns participants to a tested intervention. The registered 172 participants enrollment target is mid-sized for trials with a published cap, below the 226-participant average among 83 other Cataract trials with a reported enrollment target (24% lower).
The record links to 1 condition, with Cataract appearing as the primary indexed condition, and to 2 interventions - of which T-Pred is the first listed.
NCT00854061 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00854061 about?
NCT00854061 is a clinical study titled "Study of T-PRED(TM) Compared to Pred Forte(R) II". Study of T-PRED(TM) Compared to Pred Forte(R)
What is the current status of trial NCT00854061?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 172 participants. The study started on 2009-02. Estimated completion is 2009-08.
What conditions does trial NCT00854061 study?
This clinical trial studies the following conditions: Cataract.
What interventions are being tested in trial NCT00854061?
The interventions under investigation include: T-Pred (DRUG), Pred Forte (DRUG).
Who is sponsoring clinical trial NCT00854061?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00854061 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cataract
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00854061's enrollment target sits among peer trials
172 30th of 83 higher than 54 of 83 other Cataract trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cataract trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Efficacy and Safety of MELT-300 for Procedural Sedation in Subjects Undergoing Cataract Extraction With Lens Replacement (CELR)
RECRUITING · Phase 3
-
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)
RECRUITING · Phase 3
-
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)
RECRUITING · Phase 3
-
Safety and Efficacy of a Violet Visible Light Blocking Intraocular Lens (IOL)
COMPLETED · Phase 3
-
Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation
COMPLETED · Phase 3
-
Mapracorat Ophthalmic Suspension for the Treatment of Ocular Inflammation Following Cataract Surgery
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04801797 · 172 participants · Phase 2
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
- NCT04867317 · 172 participants · Phase 3
Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD)
- NCT05357040 · 172 participants · Phase 2
Antidepressant Effects of Nitrous Oxide
- NCT05587517 · 172 participants · Phase 2
A Clinical Trial of Interventions to Support Family Surrogates of Critically Ill Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia